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Abstract 
Bile acid research has gained great momentum since the role of bile acids as key signaling molecules in 
the enterohepatic circulation was discovered. Their physiological function in regulating their own 
homeostasis, as well as energy and lipid metabolism make them interesting targets for the pharmaceutical 
industry in the context of diseases such as bile acid induced diarrhea, bile acid induced cholestasis or 
nonalcoholic steatohepatitis. Changes in bile acid homeostasis are also linked to various types of drug-
induced liver injury (DILI). However, the key question whether bile acids are surrogate markers for 
monitoring DILI or key pathogenic players in the onset and progression of DILI is under intense 
investigation. The purpose of this review is to summarize the different facets of bile acids in the context of 
normal physiology, hereditary defects of bile acid transport and DILI. 
Introduction 
The liver is highly exposed to drugs and xenobiotics, maintains the metabolic homeostasis of the body, 
and is responsible for bile formation and biliary secretion Thus, it is not surprising that the liver is a major 
target organ of adverse drug reactions. Drug-induced liver injury can be classified as drug induced 
cholestasis, drug induced hepatitis and mixed type liver injury [1] and has been the most frequent single 
cause of safety-related drug marketing withdrawals for the past 50 years [2, 3]. DILI can resemble almost 
any form of acute or chronic liver disease (e.g. bland cholestasis, acute cholestatic hepatitis, acute hepatic 
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necrosis, acute viral hepatitis-like syndrome, immunoallergic hepatitis, cholestatic hepatitis due to 
medications, autoimmune hepatitis-like injury, sinusoidal obstruction syndrome, microvesicular steatosis 
with lactic acidosis and hepatic failure, fatty liver disease, chronic hepatitis, vanishing bile duct 
syndrome), thus necessitating standardized definitions and diagnostic criteria for DILI [4]. 
Bile acid biosynthesis and conjugation 
Bile acids (BAs) are synthesized in the liver from cholesterol [5]. The classical (neutral) pathway is 
initiated by CYP7A1 catalyzed 7α-hydroxylation, which represents the rate-limiting step in BA 
biosynthesis, leading to the formation of the two primary BAs cholic acid (CA) and chenodeoxycholic 
acid (CDCA). CA biosynthesis involves an additional hydroxylation at steroid ring position 12, catalyzed 
by CYP8B1, which controls the ratio of CA to CDCA formation. The side-chain is finally oxidized and 
cleaved by CYP27A1 [6]. This classical pathway produces at least 75 % of total BAs [7]. An alternate 
(acidic) pathway exists that is initiated by CYP27A1 and CYP7B1, leading to the formation of CDCA 
only [8, 9] [Figure 1]. In rodents, CDCA can be hydroxylated to α-muricholic acid (αMCA) and further 
epimerized to βMCA, giving rise to a pool of more polar BAs as compared to human [10]. Within the 
hepatocyte (and to a lesser extent in cholangiocytes), BAs are subjected to conjugation with glycine or 
taurine, which is catalyzed by the enzymes bile acid:CoA synthase (BACS) and bile acid:amino acid 
transferase (BAT) [11]. Dogs are predominant taurine-conjugators, rodents can form taurine and glycine 
conjugates, and non-human primates and humans show a preference for glycine conjugation. It has been 
shown that human BAT catalyzes BA conjugation with both glycine and taurine, and the extent to which 
these two conjugates are formed is determined by substrate availability [12]. This may also apply to other 
species with mixed taurine and glycine conjugation of BAs [13]. Other conjugation reactions such as 
sulfation and glucuronidation may occur, but are considered less relevant for the elimination of BAs under 
normal physiological conditions [14-20]. 
 
3 
 
Transport of bile acids 
After conjugation, BAs are excreted out of the hepatocyte across the canalicular membrane into the bile 
canaliculi, a process driven mainly by the bile salt export pump BSEP. This transport is ATP-dependent to 
facilitate BA excretion against a huge concentration gradient [21]. The relative rank order of intrinsic 
clearance for human BSEP is taurochenodeoxycholic acid (TCDCA) > taurocholic acid (TCA) > 
tauroursodeoxycholic acid (TUDCA) > glycocholic acid (GCA) [22-24]. In addition, multidrug resistance-
associated protein 2 (MRP2) mediates the transport of divalent BA (e.g. sulfated and glucuronidated BA 
conjugated with taurine or glycine), conjugated bilirubin and glutathione-conjugates into bile [25]. P-
glycoprotein (MDR1) appears to be capable to transport BAs across liver canalicular membranes to a 
certain degree [26], as shown in mice. Alternatively, basolateral export of BAs from hepatocytes and 
cholangiocytes back into the systemic circulation is mediated by multidrug resistance proteins 
MRP3/MRP4 and organic solute transporters OST-α/OST-β [21, 25, 27-29]. Cholangiocytes, similar to 
gallbladder epithelial cells, proximal renal convoluted tubule cells and ileal enterocytes, express the 
sodium-dependent BA transporter ASBT at their apical membrane domain, thereby allowing for 
cholehepatic shunting of conjugated BAs back to hepatocytes [30].  
Cholangiocytes 
The amphipathic nature of bile salts drives the solubilisation of phosphatidylcholine and cholesterol in bile 
canaliculi by forming mixed micelles, thus protecting cholangiocytes from the detergent properties of the 
bile salts. During its passage through the biliary tree, the primary hepatic bile is further modified by 
organic anion and electrolyte transport proteins expressed at the surface of biliary epithelial cells [22]. 
Cholangiocytes secrete significant amounts of bicarbonate, which raises the local pH at the apical 
membrane. Beuers et al. proposed a concept termed the “biliary bicarbonate umbrella” [31] and 
hypothesized that biliary bicarbonate secretion near the apical surface of hepatocytes and cholangiocytes 
maintains an alkaline milieu that keeps the predominantly glycine-conjugated BAs in man in their salt 
form and therefore in a more polar state. Polarity prevents molecules from passive diffusion through 
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biological membranes, which could therefore protect the integrity of cholangiocytes and periportal 
hepatocytes from the toxicity of highly concentrated bile salts. Dysregulation or functional impairment of 
this biliary bicarbonate umbrella may consequently increase the vulnerability of biliary epithelial cells 
towards biliary bile salts, and therefore contribute to various forms of chronic cholangiopathies/cholestatic 
liver diseases [31]. Supporting evidence comes from the anion exchanger AE2, which is expressed on the 
apical membrane of cholangiocytes and secrets bicarbonate into the biliary lumen in exchange for 
chloride. AE2 deficient knockout mice develop features resembling primary biliary cirrhosis [32]. Human 
genetic variants in this gene have been shown to influence susceptibility and severity of primary biliary 
cirrhosis [33]. In vitro experiments with human cholangiocytes in the presence of millimolar 
concentrations of CDCA and its glycine- and taurine conjugates confirmed the pH- and AE2-dependent 
uptake and cytotoxicity of BAs. In addition, these experiments suggested a potential protective role of the 
intact biliary glycocalyx against pH-dependent bile salt toxicity [34, 35].  
Enterohepatic cycling of bile acids 
In humans, dog and mice, bile is stored in the gallbladder (which is absent in rats) before it is released 
upon the action of the hormone cholecystokinin (CCK) into the small intestine to facilitate lipid digestion. 
BA can be deconjugated and further modified (e.g. dehydroxylation) by the intestinal microflora, giving 
rise to secondary, more hydrophobic BAs. Primary CA derived BAs (CA, GCA, TCA) are converted to 
the secondary BA deoxycholic acid (DCA), whereas primary CDCA derived BAs (CDCA, TCDCA, 
glycochenodeoxycholic acid (GCDCA)) form the secondary BA lithocholic acid (LCA). In rats, the 
primary BA βMCA is transformed to the secondary BA ωMCA by various anaerobic bacteria in a 
cooperative way [36]. BAs in the intestine are reabsorbed either by passive diffusion (e.g. DCA) or by 
active sodium-dependent transport via the ASBT transporter into enterocytes [37]. BAs escaping intestinal 
absorption are excreted via feces accounting for about 10 to 20 % loss per day [7], fecal BAs being mainly 
secondary BAs. From enterocytes, BAs enter the portal circulation via the OST-α/OST-β transporter 
heterodimer and are taken up into the liver across the hepatocyte sinusoidal membrane by the sodium- 
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(Na+)-taurocholate cotransporting polypeptide (NTCP) or by organic anion transporting polypeptides 
(OATPs). The reabsorbed BAs mix with de novo synthesized BA inside hepatocytes and can be re-
conjugated before entering the next enterohepatic cycle [38]. 
Regulation of bile acid homeostasis 
The enterohepatic FXR-FGF15/FGF19-FGFR4/βKlotho pathway assigned a new endocrine role to BAs 
[39]. Within enterocytes BAs bind to the farnesoid X nuclear receptor FXR and activate the transcription 
of fibroblast growth factor FGF15/19. FGF19 in humans, and FGF15 in rodents, is released into the portal 
blood from where it reaches the liver and binds to and activates the membrane-bound FGFR4/βKlotho 
receptor complex [40]. Activation of this receptor tyrosine kinase triggers a complex intracellular 
signaling cascade that finally results in the suppression of CYP7A1 - the key regulatory enzyme of de 
novo BA synthesis in hepatocytes. By this enterohepatic feedback circuit BAs regulate their own 
biosynthesis in an endocrine manner [41]. Additional feedback-mechanisms exist in the liver for 
controlling BA homeostasis, both at the transcriptional and posttranscriptional levels. FXR is also 
expressed in hepatocytes and regulates hepatic BA biosynthesis and transport proteins that are involved in 
hepatocellular uptake (NTCP, OATP) and excretion (BSEP, MRP2, OST-α/OST-β, MDR1). Activation of 
FXR by BAs leads to suppression of both CYP7A1, CYP8B1 and the hepatic influx transporters NTCP 
and OATP (human only), and to an upregulation of the hepatic efflux transporters BSEP, MRP2, OST-
α/OST-β, thus preventing accumulation of cytotoxic BAs within the hepatocytes under normal physiologic 
conditions [38, 42-45]. The relative potency of individual BAs to activate FXR was determined as 
CDCA>DCA>LCA. The corresponding glycine- and taurine conjugates were also shown to activate FXR 
when BA transporters were co-expressed in cellular in vitro test systems. Free and conjugated CA, 
ursodeoxycholic acid (UDCA) and α/βMCA had only minimal or no effect on FXR [46, 47]. 
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BA in health and disease 
The concept that BAs could be key players in DILI is derived from the fact that BAs are amphiphilic 
molecules with strong emulsifying detergent properties that may impair cell membrane integrity and thus 
exert cytotoxic effects. The liver is exposed to extremely high concentrations of BAs (canaliculus and 
biliary ductules: 20 to 50 mM, gallbladder: ≤ 300 mM), which makes this organ particularly vulnerable to 
BA-induced toxicity [48].  
The lipophilicity of individual BAs is believed to be a determinant of cytotoxicity, since it is the main 
driver for passive diffusion of BAs through biological membranes. In addition, the pH of the surrounding 
environment together with the pKs of the individual BA determines whether the molecule exists in its 
uncharged, protonated or salt form, which makes a significant difference for its polarity and capability to 
penetrate membranes [49, 50]. Unconjugated DCA, LCA, CDCA, but also conjugated GCDCA and 
TCDCA were reported to impair the functionality of mitochondria isolated from rat liver, which may in 
part mediate cytotoxicity [51]. Structure-activity analysis of BAs showed that the cytotoxicity of naturally 
occurring BAs can be ranked according to DCA≥LCA≥CDCA>>CA based on assessment in an 
oesophageal (HET-1A) and hepatic carcinoma (Huh7) cell line, and overall this rank order correlates with 
lipophilicity. However, the respective taurine and glycine conjugates had no cytotoxic effect on HET-1A 
cells, which lack BA transporters [52]. Conjugated BAs are fully ionized at physiological pH and are 
therefore considered membrane impermeable without active transport. Thus, intracellular toxicity 
mediated by conjugated BAs only occurs when transporters facilitate their uptake into the cell [48] or if 
their efflux is inhibited leading to intracellular accumulation. It consequently appears appropriate to 
consider transporter-mediated flux of conjugated BAs into different compartments along with potential 
interconversion reactions that may affect their cytotoxicity profile when discussing the role of BAs in 
DILI. Figure 2A illustrates the differences in the BA profiles in plasma, bile, feces and urine of dogs as 
determined by LC-MS/MS in our laboratory. 
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It is well known that different species show different BA pool compositions (Figure 2B), which adds 
additional complexity to the interpretation of preclinical data in the context of human safety assessment 
during drug development. Rodents, for example, have a higher portion of polar BAs due to the synthesis 
of a higher proportion of hydroxylated MCAs, which makes their BA pool generally less cytotoxic. 
Interestingly, genetically modified mouse models susceptible towards developing progressive familial 
intrahepatic cholestasis (PFIC) display only a mild phenotype compared to human patients. However, 
when the BA pool of these PFIC susceptible mice was “humanized” by liver-specific disruption of the 
cytochrome P450 reductase gene resulting in reduced CYP450 activity and cholic acid supplementation, a 
more hydrophobic BA pool was established and mice rapidly developed pronounced cholestasis with 
histologic liver injury [53]. These data might therefore indicate that BA pool composition and changes 
thereof could be a critical factor for the susceptibility to liver injury.  
The mutual effects of BAs on the intestinal microflora and vice versa have repeatedly been reported [54]. 
The composition of the gut microbiota and their metabolic capacity strongly affects the composition of the 
BA pool, notably its hydrophobicity, cytotoxicity and size [55]. Treatment of mice with probiotics resulted 
in enhanced deconjugation and fecal excretion of BAs, affecting ileal BA absorption and subsequent 
stimulation of hepatic de novo BA synthesis via repression of the enterohepatic FXR-FGF15/FGF19-
FGFR4 pathway [56]. Hara and coworkers reported that obesity induced changes of the gut microbiota, 
leading to increased levels of the secondary BA DCA in the enterohepatic circulation. DCA, being a 
relatively cytotoxic BA, provoked DNA damage and cellular senescence in hepatic stellate cells, which 
consequently released inflammatory and tumor-promoting factors in the liver, facilitating hepatocellular 
carcinoma development in mice previously exposed to a chemical carcinogen [57]. Drugs that impair the 
intestinal microflora can therefore indirectly affect the liver by altering the BA profile and BA induced 
cellular effects [58, 59].  
Various liver diseases are associated with impaired BA homeostasis. Genetic variations in the genes for 
FXR, BSEP and MDR3 confer susceptibility to intrahepatic cholestasis of pregnancy (ICP) - a transient 
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cholestasis in pregnant women – in association with elevated circulating levels of estrogens and 
progesterone [22]. Estrogen and progesterone metabolites, e.g. estradiol-17beta-glucuronide, were shown 
to trans-inhibit BSEP after its secretion into bile canaliculi by MRP2 [60, 61]. Increased serum levels of 
sulfated progesterone metabolites were reported to affect FXR functionality in addition to inhibiting the 
hepatocellular BA uptake and efflux transporters NTCP and BSEP [62-64], thus mechanistically linking 
the cholestatic syndrome in susceptible women to the hormonal changes arising during pregnancy. 
Consistently, drug therapy with oral contraceptives and anabolic steroids such as 17α-alkylated androgens 
were also associated with cholestasis, depending on the individual susceptibility of the recipient [65].  
Progressive familial intrahepatic cholestasis (PFIC) is an inherited early-onset cholestatic syndrome with 
progression to end-stage liver disease caused by mutations in canalicular transporter genes. Less severe 
forms of cholestasis such as benign recurrent intrahepatic cholestasis (BRIC) are linked to mutations in 
BSEP or MDR3, likely impairing expression or function of the respective transport protein [22]. 
Treatment of ICP patients with the secondary BA UDCA was reported to reduce plasma concentrations of 
sulfated steroid metabolites [66] and exert other beneficial effects [67]. These and various other examples 
illustrate the importance of intact BA homeostasis for the integrity of the liver. 
Bile acids as key players in DILI: 
Consistent with the role of BA transporter impairment in various liver diseases, inhibition of BSEP by 
drugs or their metabolites is considered an important mechanism of drug induced cholestasis and has been 
reported for cyclosporine A, rifampicin, bosentan, troglitazone and various other compounds [68].  
While drug induced cholestasis without hepatitis can be transient and is commonly less severe for the 
patient, severe irreversible drug-induced liver failure can be fatal or require organ transplantation. 
Troglitazone (TGZ) is an anti-diabetic drug that was withdrawn from the market due to acute severe 
idiosyncratic drug-induced liver injury in some patients [69-71]. Clinical observations and in vivo rat 
studies suggested, at least in part, a cholestatic mechanism for TGZ-induced hepatotoxicity, in addition to 
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a role of a reactive quinone metabolite [72, 73]. Both in human and in rat, TGZ is efficiently metabolized 
to the major metabolite TGZ-sulfate, which has a high potential to competitively inhibit BSEP and 
accumulate in the hepatocytes (apparent Ki for rat BSEP inhibition were determined as 1.3 μM for TGZ 
and 0.23 μM for TGZ-sulfate) [74]. Rat studies with TGZ demonstrated significantly reduced bile flow 
and a rapid and dose-dependent increase in plasma BA concentrations [74, 75]. A mechanism leading to 
cytotoxic intracellular bile salt accumulation due to BSEP inhibition was therefore also discussed for 
humans. Despite the disturbances in BA homeostasis, rat models failed to predict TGZ-induced 
hepatotoxicity, potentially due to interspecies differences in BA composition and the less cytotoxic BA 
pool in rodents [76].  
Jemnitz et al. investigated the effect of cholestatic drugs on TCA transport in human and rat sandwich-
cultured hepatocytes and found significant differences in TCA elimination: in human hepatocytes, equal 
fractions of TCA were eliminated via basolateral (likely by MRP3/4 efflux pumps) and canalicular 
(mainly BSEP) efflux (34.8% and 34.4 %, respectively) with a similar portion remaining within the cell 
(30.5%). In contrast, basolateral transport (71.7%) was dominant in rat hepatocytes and intracellular TCA 
accumulation was low (6.9%). Concordantly, inhibition of BSEP by TGZ treatment resulted in a 
significantly higher relative increase in intracellular TCA concentrations in human versus rat hepatocytes 
[77]. The higher rate of basolateral BA efflux in the rat in combination with the lower intracellular 
concentrations and the lower toxicity of the rodent BA pool could have a protective role in the rat and 
explain species differences in response to cholestatic or hepatotoxic drugs.  
Recently, a system pharmacology model was described that could predict species differences in TGZ-
induced hepatotoxicity due to altered BA homeostasis [76]. The model simulated a human population, 
taking into account drug/metabolite disposition, BA physiology/pathophysiology (transporter inhibition), 
hepatocyte life cycle and liver injury biomarkers and predicted TGZ-induced delayed increases in serum 
alanine transaminase and bilirubin levels. Such physiologically based pharmacokinetic models could be of 
great value for assessing adverse outcome effects due to impairment of BA homeostasis. Implementation 
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of additional compensatory regulatory networks, e.g. FXR-mediated transcriptional up- or downregulation 
of hepatic BA transporters and biosynthesis enzymes, or the endocrine FXR-FGF19/FGFR4 pathway, 
could add another valuable dimension. 
The drug bosentan, an endothelin receptor antagonist approved for pulmonary arterial hypertension, 
contains a black-box warning for hepatotoxicity. Similarly to TGZ, a mechanism involving inhibition of 
BSEP with subsequent intracellular accumulation of cytotoxic BAs and induction of liver cell damage was 
discussed [78]. Despite the inhibitory potential on rat BSEP leading to elevated serum BAs, bosentan did 
not induce hepatotoxicity in rats. Lesli et al. showed that bosentan differentially inhibits both rat and 
human NTCP in addition to BSEP. The authors concluded that the rat might be less sensitive to 
hepatotoxicity since bosentan showed stronger inhibitory potential towards rat NTCP compared to human, 
resulting in less intrahepatocyte accumulation of BAs in rats [79]. By applying a mechanistic model of 
DILI Woodhead et al. simulated whether - in response to bosentan - BA accumulation can reach toxic 
levels, both in a human and in a rat population, or not. Although the incidence of bosentan toxicity was 
underestimated, the system predicted a mild hepatocellular ATP decline and serum ALT elevation in 
human but not in rats, which was accounted for by the less toxic BA pool in rats [80].  
A recent case report described two Japanese patients who had initially received bosentan monotherapy and 
experienced liver toxicity. After dose reduction or discontinuation, liver function was normalized and 
patients received retreatment with a combination of bosentan and UDCA. Subsequent liver function tests 
did not show any abnormalities after the combined therapy [81], indicating compensatory effects by the 
treatment with UDCA. 
Impairment of BA homeostasis by a single insult, e.g. inhibition of a single hepatic BA transporter, might 
be compensated by activation of regulatory feedback pathways involving nuclear receptors (e.g. FXR), 
leading to up- or down-regulation of hepatic BA transport systems. Additionally, alternative BA efflux 
systems or detoxifying BA conjugation reactions could prevent intracellular accumulation of cytotoxic 
BAs. However, additional insults by a drug impairing the integrity of multiple compensatory pathways 
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could exceed the protective capacity of the liver and become critical for liver function. Glucuronidation of 
BAs, for example, appears to be of little relevance under normal physiologic conditions [82]. However, it 
was reported that glucuronidation may become more important under severe cholestatic conditions, since 
it allows the conversion of cytotoxic BAs into non-toxic glucuronides, which also facilitates MRP3-
mediated alternative efflux from hepatocytes into the blood for urinary elimination [16, 83-85]. Sulfation 
of BAs by sulfotransferase (e.g. SULT2A1) is another important mechanism to detoxify BAs. Sulfated 
BAs exhibit decreased toxicity and enhanced fecal and urinary excretion since they cannot be reabsorbed 
by the intestine, as exemplified by LCA sulfates. Sulfation of BAs is increased during cholestatic disease 
and might therefore play an important role under pathologic conditions [86].  
Although there are various indications that BAs might be key players in the onset of DILI, the initiation 
and progression of liver injury is usually multifactorial. Aleo et al., for example, assessed various 
compounds with Most-DILI-, Less-DILI- and No-DILI-concern and found that drugs with dual potency as 
mitochondrial and BSEP inhibitors were highly associated with more severe human DILI and more 
restrictive product safety labeling related to liver injury [87]. In the case of TGZ, reactive metabolite 
formation and mitochondrial dysfunction are considered to be critical steps in DILI pathogenesis in 
addition to inhibition of BSEP [73, 74, 88]. Inflammatory processes significantly contribute to DILI, 
which may often be triggered by reactive metabolite mediated hapten formation. However, BAs were also 
shown to induce inflammatory genes in hepatocytes and in mouse liver after bile duct ligation [89], which 
may promote hepatic inflammation during cholestasis and contribute to DILI. Besides the potential 
contribution of impaired BA homeostasis, mechanisms such as mitochondrial dysfunction, cytotoxicity, 
reactive metabolite formation, immune-mediated hypersensitivity reactions, dose and lipophilicity of a 
drug itself and combinations thereof [90, 91] seem to be important factors in the onset of acute liver 
failure in combination with individual risk factors. 
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Bile acids as surrogate markers 
Circulating total BAs are well-established clinical markers to detect liver injury and reflect a disturbance 
of normal hepatic excretory function. Changes in total BAs are usually indicative for hepatocellular and/or 
hepatobiliary injury. With the availability of new analytical multiplexing methods based on LC-MS/MS 
and GC/MS, circulating BA profiles are currently being evaluated as biomarkers for hepatotoxicity [92]. 
In an attempt to identify potential biomarkers for improved DILI detection by untargeted metabolomics, 
significant elevations of a panel of BAs in plasma and urine of rats treated with different types of 
hepatotoxins were found [93]. Other groups reported changes in metabolites derived from energy [94, 95], 
urea and BA metabolism in urine and blood of mice or rats treated with a single dose of acetaminophen 
(APAP), which strongly correlated with the development of hepatic necrosis [96]. Luo et al. evaluated by 
a targeted LC-MS/MS approach CA, GCA and TCA as potential biomarkers of liver injury in rodent 
models [97]. The authors reported that animals with histopathological signs of hepatocellular necrosis 
showed increases in all three BAs in serum, whereas animals with signs of bile duct hyperplasia displayed 
increases in only the conjugated forms GCA and TCA. They suggested that individual serum BAs might 
be a potential diagnostic marker to differentiate between different forms of liver injury [97] and 
characterized individual BA profiles in patients with liver injury and healthy volunteers [98]. Their data 
showed that total and individual BAs were strongly increased in samples from hepatic injury subjects with 
the exception of the secondary BA DCA. In addition, conjugated BAs were higher than unconjugated BAs 
in the patient group. The portion of free and conjugated CA in serum was also higher in subjects with liver 
injury compared to healthy controls. The changes induced by APAP with respect to individual BAs in 
urine and blood based on clinical and non-clinical data and their potential use as biomarkers of liver injury 
were recently reported [99]. 
While alterations in BA profiles can be the consequence of hepatotoxicity, functional inhibition of BA 
transporters in vivo may also lead to shifts in BA composition in the circulation without being the 
consequence of cellular damage of the liver. In an exploratory study with male Sprague-Dawley rats 
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treated with 20 mg/kg/day cyclosporine A (CsA) by oral gavage for 7 days, we found significant changes 
in individual plasma BA components. The unconjugated primary BAs CA, CDCA, and α/βMCA, which 
accounted for approximately 60% of the total BAs in control plasma, were significantly increased with 
CsA. While DCA plasma levels were not affected by the treatment, the unconjugated secondary BAs 
ωMCA, γMCA and UDCA tended to be increased in absolute concentrations. LCA, though present only 
in traces in plasma, was decreased. Both primary and secondary taurine-conjugated BAs were generally 
less abundant in treated animals when compared to controls. The sum of all individual BAs measured 
increased approximately 3-fold with CsA, which was mainly driven by the increase of the unconjugated 
primary BAs CA, CDCA and αMCA (Figure 2C). This complex pattern of changes in circulating BAs 
observed with CsA in rats is likely the consequence of inhibition of multiple hepatic transporters. CsA has 
the potential to inhibit both rat influx and efflux transporters in the lower micromolar range as determined 
in primary cultured rat hepatocytes and membrane vesicles, respectively (NTCP IC50 = 8.63 μM, OATPs 
IC50 = 4.55 μM, BSEP IC50 = 1.75 μM, MRP2 IC50 = 9.2 μM) [100]. Although the individual contribution 
of these transporters to CsA-induced changes in BA profiles is difficult to assign, it seems that not all BAs 
were affected in the same way. To further shed light into the complex system of BA homeostasis, it would 
be advantageous to systematically generate structure-activity relations of BAs for their various BA 
transporters. Such data could be valuable to better simulate potential BA-mediated adverse effects in 
humans, taking the different species’ BA profiles into account. 
The IMI SAFE-T consortium, a public-private partnership between industry, health authorities and 
academia, is currently evaluating BA profiles as potential markers for drug-induced BA transporter 
inhibition and liver injury [101]. The complexity of this endeavor lies in the fact that different mechanisms 
can lead to changes in BA profiles with overlapping effects. Many drugs inhibit more than one BA 
transporter and/or have effects on BA biosynthesis. In addition, the transition from BAs as early functional 
markers to assess BA transporter inhibition to surrogate biomarkers for liver injury may be difficult to 
differentiate based on thresholds. Preclinical studies can be very helpful since they allow an optimal study 
design with controlled conditions and appropriate sampling. However, the differences between species in 
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BA composition and physiology need to be considered for proper data interpretation and subsequent 
translation or extrapolation to humans. Human biosamples with a clearly defined pathology are mandatory 
for validating circulating individual BAs as biomarkers for monitoring liver integrity. 
Summary and conclusion 
Accumulation of intrahepatic cytotoxic BAs due to drug-induced disturbances of BA homeostasis appears 
to be an important contributing factor to the onset of DILI in susceptible individuals in combination with 
other key adverse events impacting liver physiology, e.g. mitochondrial dysfunction, reactive metabolite 
formation and immune-mediated responses. Circulating individual BAs’ concentrations might become 
promising sensitive and selective early markers to monitor functional impairment of the liver, allowing a 
prognostic assessment before irreversible damage occurs. 
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Figure legends 
Fig. 1: Schematic overview of hepatic BA biosynthesis, conjugation, transport and enterohepatic cycling. 
Regulatory pathways of BA homeostasis, e.g. the endocrine FXR-FGF15/19-FGFR4 pathway and 
intrahepatic regulation of BA transporters by FXR, are shown. The rodent specific MCAs are depicted in 
italic 
 
Fig. 2: A: BA profiles in dog plasma, bile, feces and urine. B: Differences in BA composition in plasma of 
mouse, rat, monkey and human. C: Changes in individual plasma BA concentrations in rats treated with 
20 mg/kg/day Cyclosporine A for 7 days. Levels of statistical significance versus controls were calculated 
using a student`s t test: * p>0.05; ** p>0.01; *** p>0.001. Unconj.1stBA: sum of unconjugated primary 
BAs. T-1stBA: sum of taurine conjugated primary BAs. T-2ndBA: sum of taurine conjugated secondary 
BAs. All data were obtained in-house by a multiplexing LC-MS/MS method enabling the analysis of 17 
BAs.  
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